But last April the FDA's cancer assessment committee finally changed course, requesting that the National Academy of Sciences conduct an in-depth review.
Kepha ngo-Ephreli odlule ikomidi lokuhlola umdlavuza le-FDA ligcine liguqule inkambo, lacela ukuthi iNational Academy of Sciences yenze isibuyekezo esijulile.